1. Home
  2. VSNT vs COGT Comparison

VSNT vs COGT Comparison

Compare VSNT & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSNT

Versant Media Group Inc. Class A Common Stock

N/A

Current Price

$38.54

Market Cap

6.0B

Sector

Industrials

ML Signal

N/A

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$34.76

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSNT
COGT
Founded
2025
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.1B
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
VSNT
COGT
Price
$38.54
$34.76
Analyst Decision
Buy
Strong Buy
Analyst Count
3
15
Target Price
$43.67
$36.21
AVG Volume (30 Days)
1.4M
1.5M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
3.79%
N/A
EPS Growth
N/A
N/A
EPS
3.49
N/A
Revenue
$6,688,000,000.00
$7,871,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,733.58
P/E Ratio
$11.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.17
$11.61
52 Week High
$45.58
$43.73

Technical Indicators

Market Signals
Indicator
VSNT
COGT
Relative Strength Index (RSI) 63.65 40.07
Support Level $38.73 $33.26
Resistance Level $42.61 $37.69
Average True Range (ATR) 1.10 1.30
MACD 0.20 -0.27
Stochastic Oscillator 75.14 22.34

Price Performance

Historical Comparison
VSNT
COGT

About VSNT Versant Media Group Inc. Class A Common Stock

Versant Media Group Inc is an independent media company comprised of NBCUniversal's cable television networks, including USA Network, CNBC, MSNBC, Oxygen, SYFY, and Golf Channel, along with complementary digital assets Fandango, Rotten Tomatoes, GolfNow, GolfPass, and SportsEngine.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: